RecruitingPhase 3NCT05125302
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Sponsor: AbbVie
Chicago, IL · Hoffman Estates, IL · +123 more sites